These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 19646755

  • 41. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.
    J Clin Oncol; 2009 Feb 01; 27(4):498-503. PubMed ID: 19075274
    [Abstract] [Full Text] [Related]

  • 42. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Gozzetti A, Candi V, Fabbri A, Schiattone L, Cencini E, Lauria F, Frasconi A, Crupi R, Raspadori D, Papini G, Defina M, Bartalucci G, Bocchia M.
    Leuk Res; 2014 Aug 01; 38(8):891-5. PubMed ID: 24934847
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W.
    Dtsch Med Wochenschr; 2002 Oct 25; 127(43):2253-8. PubMed ID: 12397539
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
    Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ.
    Blood; 2008 Aug 15; 112(4):975-80. PubMed ID: 18411418
    [Abstract] [Full Text] [Related]

  • 51. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M.
    J Clin Oncol; 2001 Mar 01; 19(5):1414-20. PubMed ID: 11230486
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
    Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M.
    Blood; 2016 Jan 14; 127(2):208-15. PubMed ID: 26486789
    [Abstract] [Full Text] [Related]

  • 54. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
    Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M.
    Cancer; 2006 Jan 15; 106(2):337-45. PubMed ID: 16353201
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
    Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA, 407 Study Investigators.
    Blood; 2011 Jun 16; 117(24):6450-8. PubMed ID: 21498674
    [Abstract] [Full Text] [Related]

  • 58. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 59. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.
    Lancet Oncol; 2019 Nov 01; 20(11):1576-1586. PubMed ID: 31582354
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.